A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals
Sandra Andorf(Cincinnati Children's Hospital Medical Center), Kari C. Nadeau(Palo Alto University), Stephen J. Galli(Stanford University), Antonella Cianferoni(Children's Hospital of Philadelphia), Hugh A. Sampson(Icahn School of Medicine at Mount Sinai), Stephen A. Tilles(University of Washington), Julie Wang(Shanghai Jiao Tong University), Manisha Desai(Center for Clinical Research (United States)), Katherine O'Laughlin(Stanford University), Amal Assa’ad(Cincinnati Children's Hospital Medical Center), Michelle B. Lierl(Cincinnati Children's Hospital Medical Center), Jonathan M. Spergel(University of Pennsylvania), Jacqueline A. Pongracic(Lurie Children's Hospital), Natasha Purington(Stanford University), Efren Rael(Stanford University), Scott H. Sicherer(Icahn School of Medicine at Mount Sinai), Divya Kumar(Stanford University), Daniel Petroni(Allergy Asthma Research Institute), Terri Brown Whitehorn, Jonathan S. Tam(University of Southern California), Rachel G. Robison(Lurie Children's Hospital), Andrew Long(Johns Hopkins University), Stephanie Logsdon(Cincinnati Children's Hospital Medical Center), Melanie Makhija(Lurie Children's Hospital), R. Sharon Chinthrajah(Stanford University)
Cited by 132
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
|Journal of Allergy and Clinical Immunology|2006|2.3k
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation
|New England Journal of Medicine|2019|1.9k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k